retatrutide trial results news today Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a TRIUMPH-1 Trial Shows Potential for

Retatrutide is the first medication in this class that hits 3 different biological targets

Side effects are typically mild and manageable

Established rheumatoid arthritis treatment requires disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, with biologic therapies for inadequate responders

As we navigate this danger zone in weight loss management with GLP-1 agonists, history offers valuable lessons

Non-starchy vegetables : leafy greens, broccoli, peppers, zucchini, green beans, cauliflower

Health Canada typically follows the FDA by 6 to 18 months, which could place Canadian pharmaceutical approval in 2028 or 2029